Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-25
    E.g., 2018-02-25

Articles

49993 items
4:39 PM, Feb 15, 2018  |  BC Extra | Company News

Roche acquiring Flatiron for $1.9B

Roche (SIX:ROG; OTCQX:RHHBY) will acquire the 87% of healthcare IT company Flatiron Health Inc. (New York, N.Y.) it does not already own for $1.9 billion in a deal expected to close this half. In 2016, Roche...
3:41 PM, Feb 15, 2018  |  BC Extra | Politics & Policy

Utah House approves bill to allow Canadian drug imports

Utah's House of Representatives voted Wednesday to approve a bill that would establish a state program to allow import of drugs from Canada. The bill seeks approval from HHS to set up a state drug...
3:29 PM, Feb 15, 2018  |  BC Extra | Company News

AI software to detect strokes gets FDA clearance

FDA approved Viz LVO Stroke Platform, an AI-based triage software from Viz.ai Inc. (San Francisco, Calif.), to detect large vessel occlusion (LVO) strokes in computed tomography (CT) images of the brain. The approval, which came...
2:43 PM, Feb 15, 2018  |  BC Extra | Financial News

Consonance Capital promotes Pyun to partner

Consonance Capital Management promoted Kevin Pyun to partner and director of research. He was the fund's primary investment analyst....
2:42 PM, Feb 15, 2018  |  BC Extra | Company News

AMAG gets second FDA approval in two weeks

FDA approved an sNDA from AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) for subcutaneous Makena hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women who spontaneously delivered one preterm baby in the past. AMAG jumped...
2:34 PM, Feb 15, 2018  |  BC Extra | Clinical News

Bavencio misses in Phase III for NSCLC

Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) said Bavencio avelumab missed the primary endpoint in the Phase III JAVELIN Lung 200 trial to treat locally advanced, unresectable, recurrent or metastatic non-small cell lung cancer in...
2:33 PM, Feb 15, 2018  |  BC Extra | Company News

Management tracks: bluebird, Sangamo

Gene therapy company bluebird bio Inc. (NASDAQ:BLUE) promoted Alison Finger to chief commercial officer from SVP of marketing and product launch. Gene editing company Sangamo Therapeutics Inc. (NASDAQ:SGMO) hired Heather Turner as SVP and general counsel....
2:21 PM, Feb 15, 2018  |  BC Extra | Financial News

Pontifax leads Abac’s €16M series A round

Abac Therapeutics S.A. (Barcelona, Spain) raised €16 million ($19.6 million) in a series A round led by Pontifax. New investors Global Health Science Fund, Caixa Capital Risc and Debiopharm Innovation Fund participated, as did existing...
11:45 AM, Feb 15, 2018  |  BC Extra | Company News

Priority Review for Agios' ivosidenib

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) said FDA accepted and granted Priority Review to an NDA for ivosidenib (AG-120) to treat relapsed or refractory acute myelogenous leukemia (AML) in patients with an isocitrate dehydrogenase 1 (IDH1) mutation....
10:01 AM, Feb 15, 2018  |  BC Extra | Politics & Policy

FDA investigating misuse, abuse of gabapentinoids

FDA Commissioner Scott Gottlieb said Thursday that the agency is investigating potential misuse and abuse of gabapentinoids. Gabapentinoids are approved to treat postherpetic neuralgia, fibromyalgia, partial onset seizures, and neuropathic pain associated with diabetes or...

Pages